Skip to content

AYALA PHARMACEUTICALS, INC.: 10-K/A filed 2013-02-14

What AYALA PHARMACEUTICALS, INC. reported in its annual report amendment filed 2013-02-14 (fiscal FY 2012): 33 published measures, 96 facts as tagged in accession 0001144204-13-009374.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-K/A (annual report amendment)
Filed
2013-02-14
Fiscal period
fiscal FY 2012
Accession
0001144204-13-009374 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AYALA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-10-313,815,797USD
At 2011-10-315,355,262USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-10-319,778,521USD
At 2011-10-3117,920,275USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-10-31-5,962,724USD
At 2011-10-31-12,565,013USD
At 2010-10-31-10,659,710USD
At 2009-10-31-15,733,328USD
At 2008-10-31-839,311USD
At 2007-10-314,267,979USD
At 2006-10-31-3,707,141USD
At 2005-10-311,751,575USD
At 2004-10-31-1,339,496USD
At 2003-12-31-806,735USD
At 2002-12-3178,557USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-11-01 to 2012-10-31-12,069,687USD366
2002-03-01 to 2012-10-31-47,557,543USD3898
2010-11-01 to 2011-10-31-8,115,740USD365
2008-11-01 to 2009-10-31929,244USD365
2007-11-01 to 2008-10-31-5,416,418USD366
2006-11-01 to 2007-10-31-2,454,453USD365
2005-11-01 to 2006-10-31-6,197,744USD365
2003-01-01 to 2003-12-31-909,745USD365
2002-03-01 to 2002-12-31-166,936USD306

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-11-01 to 2012-10-31-4,568,344USD366
2002-03-01 to 2012-10-31-34,234,103USD3898
2010-11-01 to 2011-10-31-8,942,842USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-11-01 to 2012-10-3191,844USD366
2002-03-01 to 2012-10-31241,937USD3898
2010-11-01 to 2011-10-310USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-11-01 to 2012-10-313,868,787USD366
2002-03-01 to 2012-10-3137,741,857USD3898
2010-11-01 to 2011-10-3110,227,357USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-11-01 to 2012-10-31-396,749USD366
2002-03-01 to 2012-10-31-3,507,522USD3898
2010-11-01 to 2011-10-31-296,358USD365

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2011-11-01 to 2012-10-31320,602,442shares366
2010-11-01 to 2011-10-31222,918,519shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2011-11-01 to 2012-10-31-0.04USD/shares366
2010-11-01 to 2011-10-31-0.04USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2011-11-01 to 2012-10-31-346,787USD366
2002-03-01 to 2012-10-31-1,927,260USD3898
2010-11-01 to 2011-10-31-379,472USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-10-3178,068USD
At 2011-10-310USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-11-01 to 2012-10-311,146,843USD366
2002-03-01 to 2012-10-314,980,046USD3898
2010-11-01 to 2011-10-31795,226USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-11-01 to 2012-10-31-12,334,771USD366
2002-03-01 to 2012-10-31-54,808,001USD3898
2010-11-01 to 2011-10-31-13,018,836USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-10-31894,505USD
At 2011-10-311,614,021USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-11-01 to 2012-10-314,536,528USD366
2002-03-01 to 2012-10-3114,985,865USD3898
2010-11-01 to 2011-10-314,698,983USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-10-319,339,582USD
At 2011-10-3110,895,961USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-10-315,155,797USD
At 2011-10-312,420,260USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-11-01 to 2012-10-3112,334,771USD366
2002-03-01 to 2012-10-3156,671,344USD3898
2010-11-01 to 2011-10-3113,018,836USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-11-01 to 2012-10-316,646,094USD366
2002-03-01 to 2012-10-3129,802,834USD3898
2010-11-01 to 2011-10-318,078,901USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-10-31394,804,165shares
At 2011-10-31250,173,570shares

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2012-10-312,089,099USD
At 2011-10-315,662,100USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-10-31287,518USD
At 2011-10-31195,672USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-10-31209,450USD
At 2011-10-31195,672USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2012-10-312,413,755USD
At 2011-10-312,256,852USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-10-311,367,412USD
At 2011-10-312,976,334USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2012-10-311,613,187USD
At 2011-10-313,902,725USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2011-11-01 to 2012-10-31-12,809,687USD366
2002-03-01 to 2012-10-31-49,880,113USD3898
2010-11-01 to 2011-10-31-9,654,426USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-11-01 to 2012-10-315,688,677USD366
2002-03-01 to 2012-10-3126,868,510USD3898
2010-11-01 to 2011-10-314,939,935USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2011-11-01 to 2012-10-3113,776USD366
2002-03-01 to 2012-10-31209,448USD3898
2010-11-01 to 2011-10-3128,406USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2011-11-01 to 2012-10-31148,002USD366
2002-03-01 to 2012-10-31742,642USD3898
2010-11-01 to 2011-10-31132,288USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2002-03-01 to 2012-10-3133,211USD3898
2010-11-01 to 2011-10-3133,211USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2002-03-01 to 2012-10-3111,988,230USD3898
2010-11-01 to 2011-10-310USD365

Inspect the source

Entity
AYALA PHARMACEUTICALS, INC. / CIK 0001100397
Captured
SEC response SHA-256
c79571e45bf72206000628dd6d16cc0b78424a189c2c21675f51fe12cd89a549

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001100397.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))